What is it about?
Difficulties in the use, preparation, and cost of radioactively-labeled glycosylated compounds led to this research and development study of a new gadolinium-labeled glucose compound that does not have a radioactive half-life or difficulties in its synthesis and utilization.
Featured Image
Why is it important?
Application of GDD to cancer cells also increased levels of tumor necrosis factor alpha, but did not alter blood glucose levels. Interestingly, no toxicological findings were seen in normal human kidney cells.
Perspectives
Dual application of GDD for both imaging and treatment of tumor cells could be remarkably advantageous in both the diagnosis and treatment of cancer.
Dr Masoud Ghorbani
Pasteur Institute of Iran
Read the Original
This page is a summary of: Gd3+-DTPA-DG: novel nanosized dual anticancer and molecular imaging agent, International Journal of Nanomedicine, April 2011, Dove Medical Press,
DOI: 10.2147/ijn.s17648.
You can read the full text:
Contributors
The following have contributed to this page
